Skip to content
Menu

Harrow, Inc. HROW

Full chart Compare
Set alert

Price alert · HROW

All alert types
32.13 USD -0.03 (-0.09%)

Regular-session close

32.50 +0.37 +1.15%

After hours · Nov 19, 5:06 PM ET

31.39 Day range 32.47
25.76 52-week range 54.85
YTD
-34.43%
1 year
-18.86%

5D +3.01 (+10.43%)

283032ThuFriMonTueWed31.88
Market cap
1.21B
Revenue (ttm)
303.25M
Profit margin
-9.39%
EPS (ttm)
-0.76
Shares out
37.53M
Forward P/E
17.18
YTD return
-34.43%
1-year return
-18.86%
50-day average
30.31
200-day average
37.30
Volume
761.81K
Avg volume
614.37K
Open
32.00
Previous close
32.16
Day's range
31.39 – 32.47
52-week range
25.76 – 54.85
Beta
0.17
Analysts
Strong Buy
Price target
62.25 (+93.7%)
Earnings date
Mar 1, 2027

Key statistics

Enterprise value
1.43B
Price / sales
3.98
Price / book
41.30
Revenue growth
38.60%
Free cash flow
-34.20M
Total cash
76.81M
Total debt
300.86M
Return on equity
-75.47%
Short % of float
21.03%

Fundamental scorecard

5 of 25 checks passed on HROW’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
HROW Revenue — quarterly 99.30M
HROW Net income — quarterly 9.76M
HROW EPS — quarterly 0.26

Earnings

HROW recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 1, 2027Dec 30, 20260.56———
Nov 9, 2026Sep 30, 20260.19440.25+0.06+28.60%
Aug 10, 2026Jun 30, 2026-0.17875-0.46-0.28-157.34%
May 11, 2026Mar 31, 2026-0.43-0.74-0.31-72.09%
Mar 2, 2026Dec 31, 20250.400.18-0.22-55.00%
Nov 10, 2025Sep 30, 20250.220.03-0.19-86.36%

Upgrades / downgrades

HROW analyst upgrades and downgrades
DateFirmActionFromTo
Nov 11, 2026BTIGreitBuyBuy
Oct 7, 2026BTIGreitBuyBuy
Sep 9, 2026Leerink Partnersinit—Outperform
Aug 11, 2026BTIGreitBuyBuy
Jul 21, 2026BTIGreitBuyBuy
May 13, 2026Cantor FitzgeraldmainOverweightOverweight

About Harrow, Inc.

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
harrow.com

News

Your note

Sign in to keep a note on HROW — it syncs with the Stock Master app.

Insider holders

HROW insider holders
InsiderRelationLatest transactionDateShares held
BAUM MARK LChief Executive OfficerPurchaseMay 13, 20262,996,130
BOLL ANDREW RPresidentPurchaseMay 13, 2026814,679
GRAVES ADRIENNE LDirectorPurchaseMay 17, 20261,000
OPALEYE MANAGEMENT, INC.Beneficial Owner of more than 10% of a Class of SecuritySaleMar 3, 20260
SAHAREK JOHN PChief Executive OfficerConversion of Exercise of derivative securityApr 2, 2025467,388
SHOJAEI AMIROfficerConversion of Exercise of derivative securityAug 13, 20260

Institution ownership

HROW institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.88%2,956,37394.99MSep 29, 2026
Opaleye Management Inc.5.61%2,105,00067.63MSep 29, 2026
Private Capital Management, LLC4.44%1,665,44553.51MSep 29, 2026
Vanguard Capital Management LLC3.72%1,394,73444.81MSep 29, 2026
Deep Track Capital, Lp2.85%1,069,00034.35MSep 29, 2026
State Street Corporation2.73%1,024,83932.93MSep 29, 2026

Fund ownership

HROW fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.67%1,001,44532.18MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.23%836,79326.89MSep 29, 2026
BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd.1.53%576,06918.51MJun 29, 2026
JANUS INVESTMENT FUND-Janus Henderson Venture Fund1.25%470,12115.10MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.02%383,78112.33MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.94%354,36211.39MAug 30, 2026